Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case-control study

Ramón Mazzucchelli, Sara Rodríguez-Martín, Natalia Crespí-Villarías, Alberto García-Vadillo, Miguel Gil, Laura Izquierdo-Esteban, Antonio Rodríguez-Miguel, Diana Barreira-Hernández, Encarnación Fernández-Antón, Alberto García-Lledó, Aina Pascual, Marianna Vitaloni, Josep Vergés and Francisco J. de Abajo

Abstract

Background: Several studies have reported that the use of chondroitin sulphate (CS) and glucosamine may reduce the risk of acute myocardial infarction. Although it is thought that this potential benefit could be extended to ischaemic stroke (IS), the evidence is scarce.

Objective: To test the hypothesis that the use of prescription glucosamine or CS reduces the risk of IS.

Design: Case–control study nested in an open cohort.

Methods: Patients aged 40–99 years registered in a Spanish primary healthcare database (BIFAP) during the 2002–2015 study period. From this cohort, we identified incident cases of IS, applying a case-finding algorithm and specific validation procedures, and randomly sampled five controls per case, individually matched with cases by exact age, gender and index date. Adjusted odds ratios (AORs) and 95% confidence interval (CI) were computed through a conditional logistic regression. Only new users of glucosamine or CS were considered.

Results: A total of 13,952 incident cases of IS and 69,199 controls were included. Of them, 106 cases (0.76%) and 803 controls (1.16%) were current users of glucosamine or CS at index date, yielding an AOR of 0.66 (95% CI: 0.54–0.82) for glucosamine, AOR: 0.55; 95% CI: 0.39–0.77; and for CS, AOR: 0.77; 95% CI: 0.60–0.99). The reduced risk among current users was observed in both sexes (men, AOR: 0.69; 95% CI: 0.49–0.98; women, AOR: 0.65; 95% CI: 0.50–0.85), in individuals above and below 70 years of age (AOR: 0.69; 95% CI: 0.53–0.89 and AOR: 0.59; 95% CI: 0.41–0.85, respectively), in individuals with vascular risk factors (AOR: 0.53; 95% CI: 0.39–0.74) and among current/recent users of nonsteroidal anti-inflammatory drugs (NSAIDs) (AOR: 0.71; 95% CI: 0.55–0.92). Regarding duration, the reduced risk was observed in short-term users (<365 days, AOR: 0.61; 95% CI: 0.48–0.78) while faded and became nonsignificant in long-term users (>364 days AOR: 0.86; 95% CI: 0.57–1.31).

Conclusions: Our results support a protective effect of prescription CS and glucosamine in IS, which was observed even in patients at vascular risk.

Mini abstract

Our aim was to analyse whether the use of glucosamine or chondroitin sulphate (CS) reduces the risk of ischaemic stroke (IS). We detected a significant decrease.

Keywords: chondroitin sulphate, glucosamine, stroke, SYSADOAs

Received: 19 January 2022; revised manuscript accepted: 8 June 2022.
Introduction

SYSADOAs (symptomatic slow-acting drugs for osteoarthritis) are a heterogeneous group of drugs that have the ability to modify the symptoms of osteoarthritis (OA) slowly and independently of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics or any other therapeutic option.1,2 The main drugs included in this group are glucosamine (sulphate or hydrochloride) and chondroitin sulphate (CS), widely prescribed for the treatment of OA in some countries. Glucosamine and CS are chemically different natural compounds [glucosamine is an amino sugar and CS is a glycosaminoglycan (GAG)] involved in the biosynthesis of proteoglycans (PGs).3,4 Although the efficacy of glucosamine and CS for the treatment of OA remains controversial,1,3,5 several human, animal and laboratory studies have suggested that both drugs show anti-inflammatory properties6–10 that could reduce the risk of several diseases.11–13 In this context, several recent epidemiological investigations indicate that the use of glucosamine and CS could play a role in cardiovascular disease prevention,14–17 as well as reduction of mortality,16–18 and prevention of colorectal cancer16,19–21 and other diseases.14,16,22,23 In a recent study, our group found a reduced risk of acute myocardial infarction (AMI) associated with CS in both short- and long-term users, in both men and women, in individuals above and below 70 years of age and in patients at intermediate and high vascular risk, while no protection was found in individuals at low vascular risk. By contrast, no such effect was observed with glucosamine.24

In the present case–control study nested in a study cohort of nearly 3.8 million adult patients, we examined the association between the use of glucosamine and CS, as prescription medicines and risk of ischaemic stroke (IS) using a Spanish primary healthcare database (BIFAP; Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria). We also analysed the potential effect modification by sex, age, background vascular risk and current/recent use of NSAIDs. Studies to date have included prevalent users which may have overestimated a protection by selection of less susceptible patients. To avoid this bias, we only included patients who initiated treatment with CS or glucosamine (the new-user design).25

Patients and methods

Data source

The 2016 version of BIFAP was used as the source of information for the present study. This database contains anonymised electronic medical records on clinical events, prescriptions and laboratory tests, prospectively recorded by primary care physicians (PCPs) as part of their routine clinical practice. BIFAP has been validated through multiple pharmacoepidemiological studies15,26 providing results comparable with other well-known European databases (see online supplementary file 1 – supplementary methods).27,28

Study design and selection of cases and controls

The study follows a nested case–control design. We constructed a study cohort composed by all patients registered in the database during the study period (1 January 2002–31 December 2015), who were aged 40–99 years, had at least 1-year registry with their PCPs, and had no history of cancer or IS. The follow-up started when they fulfilled all these criteria and continued until the occurrence of incident IS diagnosis, cancer diagnosis, death, 100 years of age or the end of the study period, whichever occurred first. All potential IS cases were identified using specific diagnostic codes and free text associated with the diagnosis, from which a sample of potential cases held) (see online supplemental file 1 – supplementary methods). In addition, a second validation was carried out to distinguish the most probable pathogenic subtype: cardioembolic and non-cardioembolic (including atherothrombotic, small cerebral vessel disease and unspecified/undetermined ischemic stroke), as described in online supplemental file 1 – supplementary methods.

Finally, we selected five controls per each stroke case following a risk set sampling (density-based): first, we identified all patients in the underlying cohort who, at the index date of cases, were of the same sex and age (exact) and were active in the database (to assure that at index date they were at risk) and, second, from this risk set, we randomly sampled five subjects.
Exposure definition

Drugs of interest were SYSADOAs, including glucosamine (sulphate or hydrochloride) and CS, available in Spain as prescription medicines. Although hyaluronic acid and diacerein are usually considered among SYSADOAs, they are different types of drugs and were not considered in this study. Nutraceuticals containing SYSADOAs were not considered either. Exposure was characterised as (a) ‘current users’ of SYSADOAs when the last prescription ended within 30 days before the index date; (b) ‘recent users’ when it ended between 31 and 365 days before the index date; (c) ‘past users’ when it ended more than 365 days before the index date and (d) ‘non-users’ when there was no recorded prescription of SYSADOAs before the index date.

Among current users, treatment duration was calculated by summing up consecutive prescriptions (defined as such when the interval between the end of one prescription and the start of the next was no more than 90 days). Duration was categorised as less than 365 days and 365 days or more. Daily dose was only studied for CS, as glucosamine showed no variability.

To comply with a new-user design, we restricted the analysis to SYSADOAs initiating patients. To this end, we excluded patients with recorded prescriptions for SYSADOAs before the start of follow-up.25

Potential confounding factors

The selection of potential confounding variables was based on expert knowledge avoiding data-driven methods. The following variables, recorded before the index date, were considered: number of visits to the PCP in the year prior to the index date (as a general indicator of comorbidity), body mass index (BMI), smoking status, alcohol abuse (recorded as such by the PCP), any recorded diagnosis of transient ischaemic attack (TIA), ischaemic heart disease (including history of myocardial infarction, angina pectoris and use of nitrates as an indicator of angina), atrial fibrillation, thromboembolic disease, heart failure, peripheral artery disease (PAD), hypertension, diabetes (recorded as such and/or use of glucose-lowering drugs), dyslipidaemia (recorded as such and/or use of lipid-lowering drugs), chronic obstructive pulmonary disease (COPD), knee or hip OA, rheumatoid arthritis, chronic renal failure, gout and asymptomatic hyperuricaemia. Also, we included the use of the following drugs in the 30 days prior to the index date: antiplatelet drugs, oral anticoagulants, paracetamol, metamizole, NSAIIDs, opioids, corticosteroids, calcium supplements (with or without vitamin D), angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, diuretics, proton pump inhibitors and H2-receptor antagonists.

Statistical analysis

Conditional logistic regression models were constructed to assess the association between SYSADOAs use and incident IS. We calculated adjusted odds ratios (AORs) and their corresponding 95% confidence intervals (CIs) including the main exposure plus all potential confounders described above.

Subsequently, the interaction with the following factors was evaluated: sex, age (stratified as below 70 years and above 70 years), concomitant use of NSAIIDs and background vascular risk. The latter was categorised as follows: high risk, patients with an established vascular disease: history of PAD, ischaemic heart disease, atrial fibrillation, TIA or diabetes; intermediate risk, patients with vascular risk factors (hypertension, dyslipidaemia, chronic renal failure, current smoking or obesity, defined as BMI $\geq 30$ kg/m$^2$), but none of the aforementioned established diseases; and low risk for the rest. Diabetes was considered among high-risk factors as it has been reported to be equivalent to ischaemic heart disease.29 Statistical evaluation of the interaction was performed by running fully adjusted models within the different categories of the potentially interacting variable. The AORs associated with SYSADOAs across different strata of the interacting variable were compared using the interaction test described by Altman and Bland.30 All results were considered statistically significant when the $p$ value was below 0.05.

For the stratified analysis by concomitant use of NSAIIDs and background vascular risk, as well as for the analysis restricted to patients with knee/hip OA, we performed an unconditional logistic regression including the matching variables in the model because conditional logistic regression provided unstable estimates.

Missing values for smoking (50.7%) and BMI (35.3%) were included in specific categories after
checking that the distribution of missing values did not vary across main exposure categories. Notwithstanding, as sensitivity analyses, we also run multiple imputation with chained equations (MICEs) models (see online supplemental file 1 – supplementary methods).

We conducted all analyses using STATA version 15/SE (StataCorp. College Station, Texas. 77845, USA).

**Sensitivity analyses**

Three sensitivity analyses were performed: (1) including prevalent users of SYSADOAs in the analysis; (2) using MICE models to assess the impact of missing values for BMI and smoking and (3) restricting the analysis to patients with a recorded diagnosis of knee/hip OA.

**Ethical aspects**

The BIFAP Scientific Committee granted access to fully anonymised electronic medical records (project #04/2016; approval date: 26 May 2016). Afterwards, on 1 July 2020, this committee approved specifically the analysis proposed for this study. In addition, the Research Ethics Committee of the Hospital Fundación Alcorcon (Ref 20/76) approved the study on 4 May 2020.

The present study was carried out following the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guideline (online supplemental file 1 – supplementary guideline).

**Patient and public involvement**

We engaged patients through the Osteoarthritis International Foundation (OAFI; a nonprofit association of OA patients) in the development of the research question which was based on the patients’ priorities identified by OAFI. Also, they will be involved in the reporting and dissemination of our research. OAFI did not take part in the design and conduct of the study.

**Results**

A total of 13,952 incident cases of IS and 69,199 matched controls were included (Figure 1). Characteristics are shown in Table 1. The mean age of patients was 74.6 years, and both men and women were equally represented. As expected, the prevalence of vascular risk factors and the use
### Table 1. Cases and controls characteristics.

|                         | Cases (%)  | Controls (%) | Unadjusted OR* (95% CI) |
|-------------------------|------------|--------------|-------------------------|
|                         | N = 13,952 | N = 69,199    |                         |
| Age; mean (SD)          | 74.6 (12.4) | 74.6 (12.4)  | –                       |
| Men                     | 7059 [50.59] | 35,083 [50.70] | –                       |
| Visits (last 12 months) |                         |               |                         |
| Up to 5                 | 2457 [17.61] | 19,502 [28.18] | 1 [ref.]                |
| 6–15                    | 5153 [36.93] | 25,991 [37.56] | 1.67 [1.58–1.76]        |
| 16–24                   | 3230 [23.15] | 12,750 [18.43] | 2.26 [2.13–2.40]        |
| 25+                     | 3112 [22.31] | 10,956 [15.83] | 2.66 [2.50–2.83]        |
| BMI, kg/m²               |                         |               |                         |
| Up to 24.9              | 1989 [14.26] | 9566 [13.82]  | 1 [ref.]                |
| 25–29                   | 4125 [29.57] | 20,164 [29.14] | 0.98 [0.93–1.04]        |
| 30–34                   | 2473 [17.73] | 11,336 [16.38] | 1.05 [0.98–1.12]        |
| 35–39                   | 718 [5.15]   | 2960 [4.28]   | 1.18 [1.07–1.29]        |
| 40+                     | 230 [1.65]   | 763 [1.10]    | 1.45 [1.24–1.69]        |
| Unknown                 | 4417 [31.66] | 24,410 [35.28] | 0.87 [0.82–0.92]        |
| Smoking                 |                         |               |                         |
| Never smoking           | 4599 [32.96] | 22,650 [32.73] | 1 [ref.]                |
| Current smoker          | 2219 [15.90] | 7777 [11.24]  | 1.49 [1.40–1.58]        |
| Past smoker             | 942 [6.75]   | 3683 [5.32]   | 1.32 [1.22–1.43]        |
| Unknown                 | 6192 [44.38] | 35,089 [50.71] | 0.88 [0.84–0.91]        |
| Alcohol abuse           | 408 [2.92]   | 1074 [1.55]   | 1.93 [1.72–2.17]        |
| TIA                     | 764 [5.48]   | 1591 [2.30]   | 2.50 [2.29–2.74]        |
| Ischaemic heart disease |                         |               |                         |
| Acute myocardial infarction | 850 [6.09] | 2437 [3.52]  | 1.86 [1.72–2.02]        |
| Angina pectoris^b       | 1251 [8.97]  | 4373 [6.32]  | 1.52 [1.43–1.63]        |
| Thromboembolic disease  | 313 [2.24]   | 1155 [1.67]  | 1.35 [1.19–1.54]        |
| Heart failure           | 1052 [7.54]  | 3177 [4.59]  | 1.74 [1.61–1.87]        |
| Atrial fibrillation     | 2064 [14.79] | 5271 [7.62]  | 2.18 [2.06–2.30]        |
| PAD                     | 692 [4.96]   | 1702 [2.46]  | 2.10 [1.91–2.30]        |
| Hypertension            | 8734 [62.60] | 36,767 [53.13] | 1.55 [1.49–1.61]        |

(Continued)
### Table 1. (Continued)

| Condition                          | Cases (%) N=13,952 | Controls (%) N=69,199 | Unadjusted OR<sup>a</sup> (95% CI) |
|------------------------------------|--------------------|------------------------|-----------------------------------|
| Diabetes<sup>c</sup>              | 3999 (28.66)       | 13,163 (19.02)         | 1.73 [1.65–1.80]                  |
| Dyslipidaemia<sup>d</sup>          | 6151 (44.09)       | 27,157 (39.24)         | 1.23 [1.19–1.28]                  |
| COPD                               | 1202 (8.62)        | 5064 (7.32)            | 1.21 [1.13–1.29]                  |
| Knee/hip osteoarthritis           | 1684 (12.07)       | 7835 (11.32)           | 1.08 [1.02–1.14]                  |
| Rheumatoid arthritis              | 120 (0.86)         | 606 (0.88)             | 0.99 [0.81–1.20]                  |
| Hyperuricaemia                    |                    |                        |                                   |
| Asymptomatic                      | 1089 (7.81)        | 4905 (7.09)            | 1.13 [1.06–1.21]                  |
| Gout                              | 692 (4.96)         | 2665 (3.85)            | 1.32 [1.21–1.44]                  |
| Chronic renal failure             | 796 (5.71)         | 2592 (3.75)            | 1.57 [1.44–1.70]                  |
| Current use of                    |                    |                        |                                   |
| Antiplatelet drugs                | 3733 (26.76)       | 11,360 (16.42)         | 2.14 [2.04–2.24]                  |
| Oral anticoagulants               | 1097 (7.86)        | 3835 (5.54)            | 1.53 [1.43–1.64]                  |
| Paracetamol                       | 2378 (27.52)       | 11,714 (16.93)         | 1.15 [1.08–1.22]                  |
| Metamizole                        | 693 (4.97)         | 2749 (3.97)            | 1.37 [1.26–1.50]                  |
| NSAIDs                            | 1275 (9.14)        | 6728 (9.72)            | 1.00 [0.94–1.07]                  |
| Opioids                           | 740 (5.30)         | 3061 (4.42)            | 1.28 [1.17–1.39]                  |
| Corticosteroids                   | 327 (2.34)         | 1253 (1.81)            | 1.32 [1.17–1.49]                  |
| Calcium/vitamin D supplements     | 771 (5.53)         | 3819 (5.52)            | 1.02 [0.93–1.10]                  |
| ACEIs                             | 2952 (21.16)       | 12,111 (17.50)         | 1.39 [1.33–1.46]                  |
| ARBs                              | 2474 (17.13)       | 10,613 (15.34)         | 1.26 [1.20–1.33]                  |
| CCBs                              | 2169 (15.55)       | 8566 (12.38)           | 1.41 [1.34–1.49]                  |
| Beta-blockers                     | 2050 (14.69)       | 6124 (8.85)            | 1.87 [1.77–1.98]                  |
| Alpha-blockers                    | 353 (2.53)         | 1497 (2.16)            | 1.19 [1.06–1.34]                  |
| Diuretics                         | 2551 (18.28)       | 9437 (13.64)           | 1.58 [1.50–1.66]                  |
| PPIs                              | 4592 (32.91)       | 18,848 (27.24)         | 1.43 [1.37–1.50]                  |
| H<sub>2</sub> receptor blockers   | 323 (2.32)         | 1174 (1.70)            | 1.39 [1.23–1.58]                  |

ACEIs, angiotensin-converting enzyme inhibitors; AMI, acute myocardial infarction; ARBs, angiotensin II receptor blockers; BMI, body mass index; CCBs, calcium channel blockers; CI, confidence interval; COPD, chronic obstructive pulmonary disease; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PAD, peripheral artery disease; PPIs, proton pump inhibitors; SD, standard deviation, TIA, transient ischaemic attack.

<sup>a</sup>Adjusted only for matching factors (age, sex and calendar year).

<sup>b</sup>Recorded as such, and/or when patients were using nitrates.

<sup>c</sup>Recorded as such, and/or when patients were using glucose-lowering drugs.

<sup>d</sup>Recorded as such, and/or when patients were using lipid-lowering drugs.
of cardiovascular drugs were higher for cases when compared with controls.

SYSADOAs (glucosamine and CS) use and IS risk

In total, 106 cases (0.76%) and 803 controls (1.16%) were current users of SYSADOAs, leading to an unadjusted OR of 0.65 (95% CI: 0.53–0.79), which hardly changed after full adjustment: AOR: 0.66 (95% CI: 0.54–0.82). Such decreased risk disappeared upon discontinuation (partially in recent users and completely in past users) (Table 2). When glucosamine and CS were analysed separately, we observed that the association with a reduced risk was driven by glucosamine (AOR: 0.55; 95% CI: 0.39–0.77), while a lower but still statistically significant risk reduction was observed with CS (AOR: 0.77; 95% CI: 0.60–0.99) (Table 2). Due to the very small number of patients currently using the combination of CS and glucosamine (seven cases and 45 controls), the result associated with such combination was too imprecise (AOR: 0.86; 95% CI: 0.38–1.95). By pathogenic subtype of IS, we did not find a difference: cardioembolic IS, AOR: 0.61 (95% CI: 0.41–0.92); non-cardioembolic IS, AOR: 0.69 (95% CI: 0.53–0.89).

SYSADOAs (glucosamine and CS) use and IS risk: duration of treatment and daily dose

Current use of SYSADOAs in accordance with treatment duration (less than 365 days, 365 days or more) was lower among cases (0.57% and 0.19%, respectively) than among controls (0.92% and 0.24%, respectively), leading to unadjusted ORs of 0.61 (95% CI: 0.48–0.77) and 0.80 (95% CI: 0.53–1.21), respectively, as compared with non-users. After full adjustment, results were barely modified: AOR: 0.61 (95% CI: 0.48–0.78) and AOR: 0.86 (95% CI: 0.57–1.31), respectively. Table 3 shows the results by pharmacological group and by each individual drug. Regarding dose, a significant decreased risk was only observed with CS daily doses of 800 mg or higher (AOR: 0.70; 95% CI: 0.52–0.95), though few patients used the lower dose (online supplemental file 1 – supplementary Table 2).

Discussion

In this population-based case–control study, nested in a cohort of 3,757,621 adult patients, from which around 14,000 incident IS cases emerged, we obtained the following main findings: (1) current use of SYSADOAs as prescription medicines was associated with a reduced risk of IS after full adjustment for potential confounding factors; (2) the decreased risk is observed for both cardioembolic and non-cardioembolic IS; (3) it also was observed in both sexes and in subjects above and below 70 years of age; (4) likewise,
no interaction was observed with the background vascular risk, though the reduced risk only reached statistical significance in the group with vascular risk factors but no established vascular disease; and (5) it was equally observed in the subgroup of current/recent users of NSAIDs and in the subgroup of past-users/non-users of NSAIDs.

The fact that the reduced risk of IS associated with the current use of SYSADOAs (either

---

### Table 2. Risk of ischaemic stroke associated with the use of SYSADOAs (chondroitin sulphate and glucosamine).

|                      | Cases (%)          | Controls (%)        | Unadjusted OR<sup>a</sup> (95% CI) | Adjusted OR<sup>b</sup> (95% CI) |
|----------------------|--------------------|---------------------|------------------------------------|----------------------------------|
| **SYSADOAs (all)**  |                    |                     |                                    |                                  |
| Non-users            | 13,271 (95.12)     | 65,569 (94.75)      | 1 (ref.)                           | 1 (ref.)                         |
| Current              | 106 (0.76)         | 803 (1.16)          | 0.65 (0.53–0.79)                   | 0.66 (0.54–0.82)                 |
| Recent               | 155 (1.11)         | 878 (1.27)          | 0.88 (0.74–1.04)                   | 0.85 (0.71–1.01)                 |
| Past                 | 420 (3.01)         | 1949 (2.82)         | 1.06 (0.96–1.19)                   | 0.99 (0.89–1.11)                 |
| **Glucosamine**      |                    |                     |                                    |                                  |
| Non-users            | 13,557 (97.17)     | 67,157 (97.05)      | 1 (ref.)                           | 1 (ref.)                         |
| Current              | 38 (0.27)          | 362 (0.52)          | 0.52 (0.37–0.72)                   | 0.55 (0.39–0.77)                 |
| Recent               | 80 (0.57)          | 435 (0.63)          | 0.91 (0.72–1.16)                   | 0.87 (0.67–1.11)                 |
| Past                 | 277 (1.99)         | 1245 (1.80)         | 1.10 (0.96–1.25)                   | 1.05 (0.91–1.21)                 |
| **Chondroitin sulphate** |                |                     |                                    |                                  |
| Non-users            | 13,580 (97.33)     | 67,143 (97.03)      | 1 (ref.)                           | 1 (ref.)                         |
| Current              | 75 (0.54)          | 487 (0.70)          | 0.76 (0.59–0.97)                   | 0.77 (0.60–0.99)                 |
| Recent               | 89 (0.64)          | 527 (0.76)          | 0.85 (0.68–1.07)                   | 0.82 (0.65–1.04)                 |
| Past                 | 208 (1.49)         | 1042 (1.51)         | 0.99 (0.85–1.15)                   | 0.90 (0.77–1.05)                 |
| **Chondroitin sulphate + glucosamine** | |                     |                                    |                                  |
| Non-users            | 13,866 (99.38)     | 68,731 (99.32)      | 1 (ref.)                           | 1 (ref.)                         |
| Current              | 7 (0.05)           | 45 (0.07)           | 0.78 (0.35–1.74)                   | 0.86 (0.38–1.95)                 |
| Recent               | 28 (0.20)          | 162 (0.23)          | 0.87 (0.58–1.31)                   | 0.81 (0.53–1.23)                 |
| Past                 | 51 (0.37)          | 261 (0.38)          | 0.95 (0.70–1.28)                   | 0.88 (0.64–1.20)                 |

CI, confidence interval; OR, odds ratio.
<sup>a</sup>Adjusted only for matching factors (age, sex and calendar year).
<sup>b</sup>Adjusted for matching factors (age, sex and calendar year) plus the history of transient ischaemic attack, ischaemic heart disease (acute myocardial infarction or angina pectoris—recorded as such, and/or when patients were using nitrates), thromboembolic disease, heart failure, atrial fibrillation, peripheral artery disease, hypertension, diabetes (recorded as such, and/or use of glucose-lowering medications), dyslipidaemia (recorded as such, and/or use of lipid-lowering medications), chronic obstructive pulmonary disease, knee/hip osteoarthritis, rheumatoid arthritis, asymptomatic hyperuricaemia, gout, chronic renal failure, the number of visits to the primary care practitioner in the year prior to the index date (as an indicator of comorbidities), body mass index, smoking, alcohol abuse, and use of the following drugs: antiplatelet drugs, oral anticoagulants, paracetamol, metamizole, non-steroidal anti-inflammatory drugs, opioids, corticosteroids, calcium supplements, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, diuretics, proton pump inhibitors and H<sub>2</sub>-receptor antagonists.
glucosamine or CS) waned after discontinuation (a lesser association with recent users and null among past users) is in favour of a pharmacological effect of these drugs as current and recent/past users are highly comparable populations and such differential effect is unlikely to be attributed to different personal factors.

The potential protective effect of SYSADOAs appeared to fade with long-term use (particularly evident for CS), a finding that is against a sustained biological effect of these drugs, though there may be other explanations. For instance, it is important to bear in mind that the number of patients on long-term treatment (365 days or greater) with both CS and glucosamine was rather small (23 and 9 cases, respectively), and, then, chance could have played a role, as shown by the wide CIs we found in long-term users. Also, a lower adherence at long run may account for this finding: the age of patients (mean of 74.6 years), the complex posology recommended for CS (3 months on treatment followed by a 2-month break) and, perhaps, the reduced efficacy of these drugs as OA progresses, are factors that may favour a lack of adherence to treatment at

---

**Table 3.** Risk of ischaemic stroke associated with the use of SYSADOAs (chondroitin sulphate and glucosamine) according to duration of treatment among current users.

|                      | Cases (%) | Controls (%) | Unadjusted OR\(^a\) (95% CI) | Adjusted OR\(^b\) (95% CI) |
|----------------------|-----------|--------------|-----------------------------|---------------------------|
| **SYSADOAs**         |           |              |                             |                           |
| Non-users            | 13,271 [95.12] | 65,569 [94.75] | 1 [ref.]                    | 1 [ref.]                  |
| Current users        |           |              |                             |                           |
| < 365 days           | 79 [0.57] | 638 [0.92]   | 0.61 [0.48–0.77]            | 0.61 [0.48–0.78]          |
| 365+ days            | 27 [0.19] | 165 [0.24]   | 0.80 [0.53–1.21]            | 0.86 [0.57–1.31]          |
| **Glucosamine**      |           |              |                             |                           |
| Non-users            | 13,557 [97.17] | 67,157 [97.05] | 1 [ref.]                    | 1 [ref.]                  |
| Current users        |           |              |                             |                           |
| < 365 days           | 29 [0.21] | 291 [0.42]   | 0.50 [0.34–0.73]            | 0.52 [0.35–0.77]          |
| 365+ days            | 9 [0.06]  | 71 [0.10]    | 0.61 [0.30–1.21]            | 0.66 [0.33–1.34]          |
| **Chondroitin sulphate** |         |              |                             |                           |
| Non-users            | 13,580 [97.33] | 67,143 [97.03] | 1 [ref.]                    | 1 [ref.]                  |
| Current users        |           |              |                             |                           |
| < 365 days           | 52 [0.37] | 359 [0.52]   | 0.71 [0.53–0.95]            | 0.70 [0.52–0.95]          |
| 365+ days            | 23 [0.16] | 128 [0.18]   | 0.90 [0.58–1.40]            | 0.97 [0.61–1.53]          |

CI, confidence interval; OR, odds ratio.

\(^a\)Adjusted only for matching factors [age, sex and calendar year].

\(^b\)Adjusted for matching factors [age, sex and calendar year] plus the history of transient ischaemic attack, ischaemic heart disease [acute myocardial infarction or angina pectoris – recorded as such, and/or when patients were using nitrates, thromboembolic disease, heart failure, atrial fibrillation, peripheral artery disease, hypertension, diabetes [recorded as such, and/or use of glucose-lowering medications], dyslipidaemia [recorded as such, and/or use of lipid-lowering medications], chronic obstructive pulmonary disease, knee/hip osteoarthritis, rheumatoid arthritis, asymptomatic hyperuricaemia, gout, chronic renal failure, number of visits to the primary care practitioner in the year prior to the index date [as an indicator of comorbidities], body mass index, smoking, alcohol abuse, and use of the following drugs: antiplatelet drugs, oral anticoagulants, paracetamol, metamizole, non-steroidal anti-inflammatory drugs, opioids, corticosteroids, calcium supplements, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, diuretics, proton pump inhibitors and H\(_2\)-receptor antagonists.
We have observed a reduced risk of IS in patients with vascular risk factors but not among those with established vascular diseases (including diabetes). This finding is not consistent with the results we found in a previous study on AMI, where we detected the greatest effect of SYSADOAs in the group at the highest vascular risk. We do not have a clear idea on how to explain this finding, but it is important to bear in mind that we are estimating measures of association, constructed in a multiplicative scale, and then highly influenced by the background vascular risk: the same risk reduction in an absolute scale translates into ORs of less magnitude as long as the background risk increases. In support of this explanation is the fact that the patients taking part in this study were on average 7 years older than those included in the AMI study (74.6 versus 67.0 years old). In this sense, it is interesting that the reduced risk associated with CS was of lower magnitude among patients 70 years old or older (AOR: 0.85; 95% CI: 0.62–1.16) than among younger patients (AOR: 0.57; 95%: 0.62–0.95).

Our findings are in line with several previous studies that show inverse associations of SYSADOA use with vascular risk and mortality. In a cross-sectional study of 266,844 Australian participants, glucosamine use was found to be inversely associated with risks of AMI or angina (AOR: 0.79; 95% CI: 0.73–0.86) and other heart diseases (AOR: 0.82; 95% CI: 0.76–0.89). In a prospective cohort study in the UK Biobank, glucosamine use was associated with a significantly lower risk of total cardiovascular events (AOR: 0.85; 95% CI: 0.80–0.90), cardiovascular death (AOR: 0.78; 95% CI: 0.70–0.87), coronary heart disease (AOR: 0.82; 95% CI: 0.76–0.88) and stroke (AOR: 0.91; 95% CI: 0.83–1.00). The first evidence of a possible vascular protective effect of CS in humans was raised by Morrison and colleagues in the 1970s, in an open-label clinical trial carried out with 120 patients with ischemic heart disease, assigned in a 1:1 ratio to the experimental (CS) and control group. While 42 patients (70%) in the control group had one cardiac event per month and 14 (23%) died after a 6-year follow-up, only six (10%) patients receiving CS experienced an acute cardiac event, and only four (6.6%) died. Nevertheless, no additional clinical trial using current quality standards has been carried out since then. In the Vitamins and Lifestyle (VITAL) cohort study, glucosamine and CS use was significantly associated with an 18% and 16%, respectively, lower risk of total mortality. Finally, in a recent study of our group, we observed that current use of CS was associated with a reduced risk of AMI.

Several potential mechanisms could explain the observed protective effect of SYSADOAs in vascular diseases. In the National Health and Nutrition Examination Survey (NHANES) study,
the regular use of SYSADOAs was associated with a statistically significant reduction in C-reactive protein levels, which is a marker of systemic inflammation. In animal studies, SYSADOAs have been shown to inhibit nuclear factor kappa B (NF-kB), thereby reducing several inflammation markers, thus, it is conceivable that such anti-inflammatory actions could have a preventive role in the pathophysiology of vascular diseases. In addition, glucosamine use has been shown to mimic a low-carbohydrate diet by decreasing glycolysis and increasing amino acid

Table 4. Risk of ischaemic stroke associated with the use of SYSADOAs (glucosamine/chondroitin sulphate), including prevalent users.

|                      | Cases (%) | Controls (%) | Unadjusted OR\(^a\) (95% CI) | Adjusted OR\(^b\) (95% CI) |
|----------------------|-----------|--------------|------------------------------|---------------------------|
| **SYSADOAs (all)**   |           |              |                              |                           |
| Nonusers             | 13,271 (92.66) | 65,569 (91.56) | 1 [ref.]                     | 1 [ref.]                  |
| Current              | 172 (1.20)       | 1347 (1.88)       | 0.63 [0.53–0.74]             | 0.66 [0.56–0.78]         |
| Recent               | 218 (1.52)       | 1354 (1.89)       | 0.79 [0.69–0.92]             | 0.78 [0.68–0.91]         |
| Past                 | 661 (4.62)       | 3340 (4.66)       | 0.97 [0.89–1.06]             | 0.92 [0.84–1.00]         |
| **Glucosamine**      |           |              |                              |                           |
| Non-users            | 13,641 (95.25) | 67,843 (94.74) | 1 [ref.]                     | 1 [ref.]                  |
| Current              | 83 (0.58)        | 660 (0.92)        | 0.62 [0.50–0.79]             | 0.68 [0.54–0.86]         |
| Recent               | 118 (0.82)       | 720 (1.01)        | 0.81 [0.67–0.99]             | 0.81 [0.66–0.99]         |
| Past                 | 480 (3.35)       | 2387 (3.33)       | 1.00 [0.90–1.10]             | 0.95 [0.85–1.05]         |
| **Chondroitin sulphate** |       |              |                              |                           |
| Nonusers             | 13,805 (96.39) | 68,515 (95.68) | 1 [ref.]                     | 1 [ref.]                  |
| Current              | 99 (0.69)        | 754 (1.05)        | 0.65 [0.53–0.80]             | 0.68 [0.55–0.84]         |
| Recent               | 122 (0.85)       | 777 (1.09)        | 0.78 [0.64–0.94]             | 0.77 [0.63–0.94]         |
| Past                 | 296 (2.07)       | 1564 (2.18)       | 0.94 [0.82–1.06]             | 0.88 [0.77–1.00]         |
| **Chondroitin sulphate + glucosamine** |       |              |                              |                           |
| Nonusers             | 14,175 (98.97) | 70,789 (98.85) | 1 [ref.]                     | 1 [ref.]                  |
| Current              | 10 (0.07)        | 65 (0.09)         | 0.77 [0.39–1.49]             | 0.85 [0.43–1.68]         |
| Recent               | 47 (0.33)        | 276 (0.39)        | 0.85 [0.62–1.16]             | 0.83 [0.61–1.15]         |
| Past                 | 90 (0.63)        | 480 (0.67)        | 0.94 [0.75–1.17]             | 0.88 [0.69–1.11]         |

CI, confidence interval; OR, odds ratio.

\(^a\)Adjusted only for matching factors (age, sex and calendar year).

\(^b\)Adjusted for matching factors (age, sex and calendar year) plus the history of transient ischaemic attack, ischaemic heart disease [acute myocardial infarction or angina pectoris – recorded as such, and/or when patients were using nitrates], thromboembolic disease, heart failure, atrial fibrillation, peripheral artery disease, hypertension, diabetes (recorded as such, and/or use of glucose-lowering medications), dyslipidaemia (recorded as such, and/or use of lipid-lowering medications), chronic obstructive pulmonary disease, knee/hip osteoarthritis, rheumatoid arthritis, asymptomatic hyperuricaemia and gout, chronic renal failure, the number of visits to the primary care practitioner in the year prior to the index date (as an indicator of comorbidities), body mass index, smoking, alcohol abuse, and use of the following drugs: antiplatelet drugs, oral anticoagulants, paracetamol, metamizole, nonsteroidal anti-inflammatory drugs, opioids, corticosteroids, calcium supplements, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, diuretics, proton pump inhibitors and H\(_2\)-receptor antagonists.

journals.sagepub.com/home/tab
catabolism in mice. Other mechanisms could also be involved, such as the role of PGs and GAGs in atherosclerosis. The luminal surface of the endothelium is covered by a gelatinous layer, the glycocalyx, composed of glycoproteins (GAGs and PGs), with CS being one of the most abundant GAGs. Glycocalyx is involved in multiple physiological processes of the endothelium: filtration of fluids and macromolecules, regulation of vascular tone and haemostasis, as well as regulation of neutrophil migration across the endothelium. In recent years, PGs and GAGs in the

### Table 5. Risk of ischaemic stroke associated with the use of SYSADOAs (chondroitin sulphate and glucosamine) among patients with a record of knee/hip osteoarthritis.

|                  | Cases (%) | Controls (%) | Unadjusted OR | Adjusted OR |
|------------------|-----------|--------------|---------------|-------------|
|                  | N = 1684  | N = 7835     | (95% CI)      | (95% CI)    |
| SYSADOAs (all)   |           |              | 1 (ref.)      | 1 (ref.)    |
| Non-users        | 1446 [85.87] | 6654 [84.93] |               |             |
| Current          | 37 [2.20]  | 285 [3.64]   | 0.59 [0.42–0.84] | 0.64 [0.45–0.92] |
| Recent           | 58 [3.44]  | 263 [3.36]   | 1.01 [0.76–1.35] | 1.10 [0.81–1.49] |
| Past             | 143 [8.49] | 633 [8.08]   | 1.01 [0.83–1.23] | 1.02 [0.83–1.25] |
| Glucosamine      |           |              |               |             |
| Non-users        | 1545 [91.75] | 7112 [90.77] | 1 (ref.)      | 1 (ref.)    |
| Current          | 11 [0.65]  | 140 [1.79]   | 0.36 [0.20–0.68] | 0.40 [0.21–0.74] |
| Recent           | 26 [1.54]  | 152 [1.94]   | 0.80 [0.52–1.21] | 0.90 [0.58–1.39] |
| Past             | 102 [6.06] | 431 [5.50]   | 1.07 [0.86–1.34] | 1.09 [0.86–1.38] |
| Chondroitin sulphate |     |              |               |             |
| Non-users        | 1550 [92.04] | 7210 [92.02] | 1 (ref.)      | 1 (ref.)    |
| Current          | 29 [1.72]  | 161 [2.05]   | 0.82 [0.55–1.23] | 0.89 [0.60–1.34] |
| Recent           | 35 [2.08]  | 137 [1.75]   | 1.17 [0.80–1.71] | 1.20 [0.81–1.77] |
| Past             | 70 [4.16]  | 327 [4.17]   | 0.96 [0.74–1.25] | 0.97 [0.73–1.28] |
| Chondroitin sulphate + glucosamine |     |              |               |             |
| Non-users        | 1649 [97.92] | 7668 [97.87] | 1 (ref.)      | 1 (ref.)    |
| Current          | 3 [0.18]   | 16 [0.20]    | 0.85 [0.25–2.93] | 0.95 [0.27–3.36] |
| Recent           | 12 [0.71]  | 52 [0.66]    | 1.07 [0.57–2.00] | 1.01 [0.52–1.96] |
| Past             | 20 [1.19]  | 99 [1.26]    | 0.91 [0.56–1.48] | 0.99 [0.60–1.64] |

CI, confidence interval; OR, odds ratio.

aAdjusted only for matching factors (age, sex and calendar year).

bAdjusted for matching factors (age, sex and calendar year) plus the history of transient ischaemic attack, ischaemic heart disease (acute myocardial infarction or angina pectoris – recorded as such, and/or when patients were using nitrates), thromboembolic disease, heart failure, atrial fibrillation, peripheral artery disease, hypertension, diabetes (recorded as such, and/or use of glucose-lowering medications), dyslipidaemia (recorded as such, and/or use of lipid-lowering medications), chronic obstructive pulmonary disease, rheumatoid arthritis, asymptomatic hyperuricaemia, gout, chronic renal failure, the number of visits to the primary care practitioner in the year prior to the index date (as an indicator of comorbidities), body mass index, smoking, alcohol abuse, and use of the following drugs: antiplatelet drugs, oral anticoagulants, paracetamol, metamizole, non-steroidal anti-inflammatory drugs, opioids, corticosteroids, calcium supplements, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, diuretics, proton pump inhibitors and H2-receptor antagonists.
glycocalyx have been postulated to play a role in the initiation and progression of atherosclerosis. Interestingly, Melgar-Lesmes et al. have observed in mice that CS directly latches onto the atheromatous plaque, drastically reducing its size, reduces tumour necrosis factor (TNF) effects, heals endothelial injury and decreases the monocyte/macrophage differentiation into foam cells. Furthermore, mice receiving CS showed 100% survival as compared with 83% of the control group.

The strengths of the present study are the following: (1) although the access to the data for researchers was retrospective, primary clinicians collect the data prospectively, including all prescriptions filled (CS and glucosamine are both prescription drugs in Spain, reimbursed by the National Health System); (2) the sample size of the study was large and allowed us to estimate risks with reasonable precision; (3) researchers who conducted the validation of IS cases were fully blinded to drug exposure to avoid a differential misclassification of the event; (4) controls were randomly extracted from the person-time of the underlying cohort to make sure that they represent the population exposure (density sampling), this way, avoiding a selection bias and assuring that the ORs obtained are unbiased estimates of the incidence rate ratios; (5) only ‘new users’ were considered in the main analysis thus avoiding a ‘prevalent-user’ bias; and (6) all sensitivity analyses yielded similar results to the main analysis, including the one restricted to patients with vascular risk factors, which was not considered in the present study. Actually, patients who used nutraceuticals were not recorded in the database and, then, classified as ‘non-users’, a potential misclassification that, if relevant, it would have diluted the magnitude of the effect of prescription SYSADOAs.

Conclusion

The results of the present study support the hypothesis that the use of SYSADOAs, as prescription medicines, is associated with a reduced risk of IS that was observed in both men and women and in individuals older and younger than 70 years. Importantly, such association with a risk reduction of IS was even observed in patients who were current/recent users of NSAIDs and in patients with vascular risk factors.

Declarations

Ethics approval and consent to participate
The BIFAP Scientific Committee granted access to fully anonymised electronic medical records (project #04/2016; approval date 26 May 2016). Afterwards, on 1 July 2020, this committee approved specifically the analysis proposed for this study. In addition, the Research Ethics Committee of the Hospital Fundación Alcorcon (Ref. 20/76) approved the study on 4 May 2020, which granted a waiver to obtain the informed consent, as all data were fully pseudonymised and investigators had no access to personal data.

Consent for publication
All authors read and approved the final version of the manuscript.

Author contributions
Ramón Mazzucchelli: Conceptualisation; Investigation; Supervision; Visualization; Writing – original draft; Writing – review & editing.
Sara Rodríguez-Martín: Conceptualisation; Data curation; Formal analysis; Investigation; Methodology; Software; Validation; Visualization; Writing – original draft; Writing – review & editing.
Natalia Crespí-Villarías: Investigation; Writing – review & editing.

Alberto García-Vadillo: Conceptualisation; Investigation; Writing – review & editing.

Miguel Gil: Data curation; Investigation; Software; Writing – review & editing.

Laura Izquierdo-Esteban: Investigation; Writing – review & editing.

Antonio Rodríguez-Miguel: Investigation; Writing – review & editing.

Diana Barreira-Hernández: Investigation; Writing – review & editing.

Encarnación Fernández-Anton: Investigation; Writing – review & editing.

Alberto García-Lledó: Investigation; Writing – review & editing.

Aina Pascual: Investigation; Writing – review & editing.

Marianna Vitaloni: Investigation; Writing – review & editing.

Josep Vergés: Investigation; Writing – review & editing.

Francisco J. De Abajo: Conceptualisation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Visualisation; Writing – original draft; Writing – review & editing

Acknowledgements
The authors would like to thank the excellent collaboration of primary care practitioners participating in BIFAP. They are also in debt with the staff members of the BIFAP Unit. The database BIFAP is fully funded by the Spanish Agency for Medicines and Medical Devices (AEMPS) and make the data available for free to professionals from Academia and the National Health System The views expressed in the paper are from authors and do not represent the view of the AEMPS. Finally, they thank the support and feedback of osteoarthritis patients represented in OAFI.

Funding
The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by an unrestricted research grant from OAFI (Osteoarthritis Foundation International), a non-profit association of osteoarthritis patients. OAFI had no role in study design, collection and analysis, but qualified members of OAFI took part in the interpretation of data and writing of the report as well as in the decision to submit the paper for publication.

Competing interests
The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Francisco J. de Abajo has received unrestricted research grants from Sanofi-Pasteur, and Institute of Health Carlos III, for research projects different from this one. Ramón Mazzucchelli has received research grants from Pfizer, Roche, Amgen and Sociedad de Reumatología de la Comunidad de Madrid (SORCOM) for research projects different from this one. The rest of the authors declare that there is no conflict of interest.

Availability of data and materials
Not applicable.

ORCID iDs
Ramón Mazzucchelli https://orcid.org/0000-0002-1343-4719
Francisco J. De Abajo https://orcid.org/0000-0001-9119-8646

Supplemental material
Supplemental material for this article is available online.

References
1. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med* 2006; 354: 795–808.
2. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). *Ann Rheum Dis* 2003; 62: 1145–1155.
3. Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. *Arzneimittelforschung* 1995; 45: 918–925.
4. Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. *Osteoarthr Cartilage* 2007; 15: 764–772.

5. Wandel S, Juni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ* 2010; 341: c4675.

6. Largo R, Martínez-Calatrava MJ, Sánchez-Pernaute O, et al. Effect of chondroitin sulphate in systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. *Am J Physiol Heart Circ Physiol* 2009; 297: H268–H276.

7. Herrero-Beaumont G, Marcos ME, Sánchez-Pernaute O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis: chondroitin sulphate in atherosclerosis. *Br J Pharmacol* 2009; 154: 843–851.

8. Herrero-Beaumont G and Largo R. Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation? *Ann Rheum Dis* 2020; 79: 1261–1263.

9. Ronca F, Palmieri L, Panicucci P, et al. Anti-inflammatory activity of chondroitin sulfate. *Osteoarthr Cartilage* 1998; 6(Suppl. A): 14–21.

10. Kantor ED, Lampe JW, Vaughan TL, et al. Association between use of specialty dietary supplements and C-reactive protein concentrations. *Am J Epidemiol* 2012; 176: 1002–1013.

11. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. *Nature* 2008; 454: 436–444.

12. Willerson JT and Ridker PM. Inflammation as a cardiovascular risk factor. *Circulation* 2004; 109: II2–II10.

13. Grivennikov SI, Greten FR and Karin M. Immunity, inflammation, and cancer. *Cell* 2010; 140: 883–899.

14. Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. *BMJ* 2019; 365: 11628.

15. de Abajo FJ, Gil MJ, Garcia Poza P, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. *Pharmacoepidemiol Drug Saf* 2014; 23: 1128–1138.

16. Li Z-H, Gao X, Chung VC, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. *Ann Rheum Dis* 2020; 79: 829–836.

17. King DE and Xiang J. Glucosamine/chondroitin and mortality in a US NHANES cohort. *J Am Board Fam Med* 2020; 33: 842–847.

18. Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. *Eur J Epidemiol* 2012; 27: 593–603.

19. Ibanez-Sanz G, Diez-Villanueva A, Vilorio-Marques L, et al. Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study. *Sci Rep* 2018; 8: 2040–2046.

20. Kantor ED, Lampe JW, Peters U, et al. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. *Cancer Causes Control* 2013; 24: 1137–1146.

21. Kantor ED, Zhang X, Wu K, et al. Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: results from the Nurses’ Health Study and Health Professionals follow-up study. *Int J Cancer* 2016; 139: 1949–1957.

22. Murphy RK, Ketzler L, Rice RD, et al. Oral glucosamine supplements as a possible ocular hypertensive agent. *JAMA Ophthalmol* 2013; 131: 955–957.

23. Shmagel A, Demmer R, Knights D, et al. The effects of glucosamine and chondroitin sulfate on gut microbial composition: a systematic review of evidence from animal and human studies. *Nutrients* 2019; 11: 294.

24. Mazzucchelli R, Rodriguez-Martín S, García-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: a nested case-control study. *PLoS ONE* 2021; 16: e0253932.

25. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol* 2003; 158: 915–920.

26. Requena G, Huerta C, Gardarsdottir H, et al. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. *Pharmacoepidemiol Drug Saf* 2016; 25(Suppl. 1): 66–78.

27. Souverein PC, Abbing-Karahagopian V, Martin E, et al. Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of
antidepressant use and risk of hip/femur fractures. *Pharmacoepidemiol Drug Saf* 2016; 25(Suppl. 1): 88–102.

28. Brauer R, Ruigómez A, Downey G, et al. Prevalence of antibiotic use: a comparison across various European health care data sources. *Pharmacoepidemiol Drug Saf* 2016; 25(Suppl. 1): 11–20.

29. Juutilainen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a ‘coronary heart disease equivalent’: an 18-year prospective population-based study in Finnish subjects. *Diabetes Care* 2005; 28: 2901–2907.

30. Altman DG and Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003; 326: 219.

31. Groenwold RHH, White IR, Donders ART, et al. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. *CMAJ* 2012; 184: 1265–1269.

32. Azur MJ, Stuart EA, Frangakis C, et al. Multiple imputation by chained equations: what is it and how does it work. *Int J Methods Psychiatr Res* 2011; 20: 40–49.

33. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370: 1453–1457.

34. Sibbritt D, Adams J, Lui CW, et al. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. *PLoS ONE* 2012; 7: e41540.

35. Morrison LM. Reduction of ischemic coronary heart disease by chondroitin sulfate A. *Angiology* 1971; 22: 165–174.

36. Morrison LM and Enrick N. Coronary heart disease: reduction of death rate by chondroitin sulfate A. *Angiology* 1973; 24: 269–287.

37. Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. *Am J Clin Nutr* 2010; 91: 1791–1800.

38. Navarro SL, White E, Kantor ED, et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. *PLoS ONE* 2015; 10: e0117534.

39. Zou L, Yang S, Champattanachai V, et al. Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-κB signaling. *Am J Physiol Heart Circ Physiol* 2009; 296: H515–H523.

40. Liu J, Marchase RB and Chatham JC. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. *Am J Physiol Heart Circ Physiol* 2007; 293: H1391–H1399.

41. Xing D, Feng W, Not LG, et al. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endothelial arterial injury. *Am J Physiol Heart Circ Physiol* 2008; 295: H335–H342.

42. Duan W, Paka L and Pillarissetti S. Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. *Cardiovasc Diabetol* 2005; 4: 16.

43. Weimer S, Priebs J, Kuhlow D, et al. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. *Natcommun* 2014; 5: 3563.

44. Masola V, Zaza G, Onisto M, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. *Int Angiol* 2014; 33: 243–254.

45. Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. *Pflugers Arch* 2007; 454: 345–359.

46. Melgar-Lesmes P, Sánchez-Herrero A, Lozano-Juan F, et al. Chondroitin sulphate attenuates atherosclerosis in ApoE knockout mice involving cellular regulation of the inflammatory response. *Thromb Haemost* 2018; 118: 1329–1339.